Holdings in Company

Paris, France and Camberley, UK – 26 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 26 January 2021 that, as at 25 January 2021 BlackRock Inc.’s holding in the Company on a voting and capital basis is 3.02% (2,132,372 shares). http://novacyt.com/wp-content/uploads/2021/01/Novacyt-BlackRock-holdings-26.01.2021-ENGLISH.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 13 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 12 January 2021 that, as at 11 January 2021 BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.95% (2,085,368 shares). http://novacyt.com/wp-content/uploads/2021/01/Novacyt-BlackRock-holdings-13.01.2021-ENGLISH.pdf

Visit Page

Executive Management and Proposed Board Changes

Paris, France and Camberley, UK – 5 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that James McCarthy has been appointed as Chief Financial Officer (CFO), whilst Anthony Dyer has taken on a new role as Chief Corporate Development Officer (CCDO). Both appointments are with immediate effect.

Visit Page